The Predictive Role of ERCC1 Status in Oxaliplatin Based Neoadjuvant Therapy for Metastatic Colorectal Cancer (mCRC) to the Liver

被引：6

作者：

Geva, Ravit ^{[1
]}

Shamai, Sivan ^{[1
]}

Brazowsky, Eli ^{[2
]}

Paoulas, Michael ^{[2
,3
]}

Ben-Haim, Mendi ^{[2
,3
]}

Johnstone, Elaine ^{[7
]}

Alex, Beny ^{[4
,5
,6
]}

Shacham-Shmueli, Einat ^{[1
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Div Oncol, Gastrointestinal Malignancies Serv, IL-6423906 Tel Aviv, Israel

[2] Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-6423906 Tel Aviv, Israel

[3] Tel Aviv Sourasky Med Ctr, Div Surg, IL-6423906 Tel Aviv, Israel

[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

[5] Rambam Med Ctr, Div Oncol, Haifa, Israel

[6] Technion Israel Inst Technol, Haifa, Israel

[7] Univ Oxford, Dept Oncol, Oxford OX1 2JD, England

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 04期

关键词：

Metastatic colorectal cancer; ERCC1; Oxaliplatin; PREOPERATIVE CHEMOTHERAPY; THYMIDYLATE SYNTHASE; GENE-EXPRESSION; RESECTION; SURVIVAL; SURGERY; STEATOHEPATITIS; 5-FLUOROURACIL; INCREASE;

D O I：

10.3109/07357907.2014.998834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Increased expression of excision repair cross-complementing 1 (ERCC1) inmCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgicalmargins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

引用

页码：89 / 97

页数：9

共 50 条

[11] Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy
Yeh, Yung-Sung
Chen, Yi-Ting
Tsai, Hsiang-Lin
Huang, Ching-Wen
Ma, Cheng-Jen
Su, Wei-Chih
Huang, Chun-Ming
Huang, Ming-Yii
Hu, Huang-Ming
Lu, Chien-Yu
Wang, Jaw-Yuan
PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (02) : 1105 - 1116
[12] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
P Li
Y J Fang
F Li
Q J Ou
G Chen
G Ma
British Journal of Cancer, 2013, 108 : 1238 - 1244
[13] Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis
Kobayashi, Hirotoshi
Sugihara, Kenichi
Uetaki, Hiroyuki
Higuchi, Tetsuro
Yasuno, Masamichi
Enomoto, Masayuki
Iida, Satoru
Azuma, Mizutomo
Mori, Ryutaro
Omori, Akiko
Lenz, Heinz-Josef
Danenberg, Kathleen D.
Danenberg, Peter V.
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) : 1257 - 1262
[14] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
Li, P.
Fang, Y. J.
Li, F.
Ou, Q. J.
Chen, G.
Ma, G.
BRITISH JOURNAL OF CANCER, 2013, 108 (06) : 1238 - 1244
[15] GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
Li, Hui-Yan
Ge, Xin
Huang, Guang-Ming
Li, Kai-Yu
Zhao, Jing-Quan
Yu, Xi-Miao
Bi, Wen-Si
Wang, Yu-Lin
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3465 - 3469
[16] Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy
Zhang, Y. Y.
Gu, K. S.
Wu, H. Y.
Yang, F.
Bu, L. J.
Zhao, C. C.
Zhang, Y. R.
GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 15921 - 15929
[17] ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy
Rumiato, Enrica
Cavallin, Francesco
Boldrin, Elisa
Cagol, Matteo
Alfieri, Rita
Basso, Daniela
Castoro, Carlo
Ancona, Ermanno
Amadori, Alberto
Ruol, Alberto
Saggioro, Daniela
PHARMACOGENETICS AND GENOMICS, 2013, 23 (11) : 597 - 604
[18] Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer
Kawashima, Atsunari
Takayama, Hitoshi
Kawamura, Norihiko
Doi, Noriteru
Sato, Mototaka
Hatano, Koji
Nagahara, Akira
Uemura, Motohide
Nakai, Yasutomo
Nishimura, Kensaku
Miyoshi, Susumu
Kawano, Kiyoshi
Nishimura, Kazuo
Nonomura, Norio
Tsujimura, Akira
ONCOLOGY LETTERS, 2012, 4 (01) : 15 - 21
[19] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
M Basso
A Strippoli
A Orlandi
M Martini
M A Calegari
G Schinzari
M Di Salvatore
T Cenci
A Cassano
L M Larocca
C Barone
British Journal of Cancer, 2013, 108 : 115 - 120
[20] KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
Basso, M.
Strippoli, A.
Orlandi, A.
Martini, M.
Calegari, M. A.
Schinzari, G.
Di Salvatore, M.
Cenci, T.
Cassano, A.
Larocca, L. M.
Barone, C.
BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 115 - 120

← 1 2 3 4 5 →